Gilder Gagnon Howe & Co. LLC lessened its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 5.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,120,555 shares of the biopharmaceutical company’s stock after selling 64,825 shares during the period. Alnylam Pharmaceuticals comprises approximately 1.9% of Gilder Gagnon Howe & Co. LLC’s portfolio, making the stock its 9th biggest position. Gilder Gagnon Howe & Co. LLC owned about 1.22% of Alnylam Pharmaceuticals worth $131,654,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the company. New York State Common Retirement Fund boosted its position in shares of Alnylam Pharmaceuticals by 6.7% in the third quarter. New York State Common Retirement Fund now owns 216,488 shares of the biopharmaceutical company’s stock worth $25,435,000 after buying an additional 13,500 shares during the period. Candriam Luxembourg S.C.A. boosted its position in Alnylam Pharmaceuticals by 42.9% during the third quarter. Candriam Luxembourg S.C.A. now owns 120,000 shares of the biopharmaceutical company’s stock valued at $14,099,000 after purchasing an additional 36,000 shares during the last quarter. Bradley Foster & Sargent Inc. CT boosted its position in Alnylam Pharmaceuticals by 100.1% during the third quarter. Bradley Foster & Sargent Inc. CT now owns 8,235 shares of the biopharmaceutical company’s stock valued at $968,000 after purchasing an additional 4,120 shares during the last quarter. Watch Point Trust Co acquired a new stake in Alnylam Pharmaceuticals during the third quarter valued at $235,000. Finally, State of Wisconsin Investment Board boosted its position in Alnylam Pharmaceuticals by 8.5% during the third quarter. State of Wisconsin Investment Board now owns 16,294 shares of the biopharmaceutical company’s stock valued at $1,914,000 after purchasing an additional 1,282 shares during the last quarter. 92.73% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals, Inc. (ALNY) traded up $2.30 during midday trading on Monday, reaching $139.98. The company’s stock had a trading volume of 1,386,900 shares, compared to its average volume of 1,120,946. The company has a debt-to-equity ratio of 0.14, a quick ratio of 9.83 and a current ratio of 9.83. Alnylam Pharmaceuticals, Inc. has a 12 month low of $35.98 and a 12 month high of $147.63.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.11). The company had revenue of $17.10 million for the quarter, compared to analyst estimates of $28.15 million. Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. The firm’s revenue for the quarter was up 24.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.21) earnings per share. sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -5.25 EPS for the current year.

ALNY has been the subject of a number of research reports. Needham & Company LLC reissued a “buy” rating and set a $85.00 price objective (down previously from $98.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, September 7th. BMO Capital Markets reissued an “outperform” rating and set a $99.00 price objective (down previously from $105.00) on shares of Alnylam Pharmaceuticals in a research report on Wednesday, September 6th. Instinet initiated coverage on Alnylam Pharmaceuticals in a research report on Friday, September 15th. They set a “reduce” rating and a $56.00 price objective for the company. Piper Jaffray Companies reissued an “overweight” rating and set a $110.00 price objective (down previously from $126.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, September 7th. Finally, Leerink Swann reissued a “market perform” rating and set a $72.00 price objective (down previously from $83.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, September 8th. They noted that the move was a valuation call. Three research analysts have rated the stock with a sell rating, six have given a hold rating and seventeen have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $114.57.

In other news, President Barry E. Greene sold 76,815 shares of the business’s stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $100.00, for a total value of $7,681,500.00. Following the transaction, the president now directly owns 165,399 shares of the company’s stock, valued at approximately $16,539,900. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, President Barry E. Greene sold 85,316 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $125.00, for a total value of $10,664,500.00. The disclosure for this sale can be found here. Insiders sold a total of 215,797 shares of company stock worth $25,035,072 over the last three months. 4.30% of the stock is owned by company insiders.

COPYRIGHT VIOLATION WARNING: “Alnylam Pharmaceuticals, Inc. (ALNY) Shares Sold by Gilder Gagnon Howe & Co. LLC” was posted by Daily Political and is the property of of Daily Political. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/11/13/alnylam-pharmaceuticals-inc-alny-shares-sold-by-gilder-gagnon-howe-co-llc.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.